Journal Article DKFZ-2022-01105

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Rgs16 promotes antitumor CD8+ T cell exhaustion.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2022
AAAS Washington, DC

Science immunology 7(71), eabh1873 () [10.1126/sciimmunol.abh1873]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: T cells become functionally exhausted in tumors, limiting T cell-based immunotherapies. Although several transcription factors regulating the exhausted T (Tex) cell differentiation are known, comparatively little is known about the regulators of Tex cell survival. Here, we reported that the regulator of G protein signaling 16 (Rgs-16) suppressed Tex cell survival in tumors. By performing lineage tracing using reporter mice in which mCherry marked Rgs16-expressing cells, we identified that Rgs16+CD8+ tumor-infiltrating lymphocytes (TILs) were terminally differentiated, expressed low levels of T cell factor 1 (Tcf1), and underwent apoptosis as early as 6 days after the onset of Rgs16 expression. Rgs16 deficiency inhibited CD8+ T cell apoptosis and promoted antitumor effector functions of CD8+ T cells. Furthermore, Rgs16 deficiency synergized with programmed cell death protein 1 (PD-1) blockade to enhance antitumor CD8+ T cell responses. Proteomics revealed that Rgs16 interacted with the scaffold protein IQGAP1, suppressed the recruitment of Ras and B-Raf, and inhibited Erk1 activation. Rgs16 deficiency enhanced antitumor CD8+ TIL survival in an Erk1-dependent manner. Loss of function of Erk1 decreased antitumor functions of Rgs16-deficient CD8+ T cells. RGS16 mRNA expression levels in CD8+ TILs of patients with melanoma negatively correlated with genes associated with T cell stemness, such as SELL, TCF7, and IL7R, and predicted low responses to PD-1 blockade. This study uncovers Rgs16 as an inhibitor of Tex cell survival in tumors and has implications for improving T cell-based immunotherapies.

Classification:

Note: #EA:D192#LA:D192# / HI-TRON

Contributing Institute(s):
  1. T-Zell-Metabolismus (D192)
  2. W610 Core Facility Omics IT (W610)
  3. Gruppe van der Hoeven (W450)
  4. DKFZ -Bayer Healthcare Joint (D220)
  5. NWG Tumorprogression und Metastasierung (A013)
  6. A190 Vaskuläre Onkologie und Metastasierung (A190)
  7. Monoklonale Antikörper (W170)
Research Program(s):
  1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2022
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Essential Science Indicators ; IF >= 30 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2022-05-30, last modified 2024-02-29



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)